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Abstract
Background—Viral suppression is a key indicator of antiretroviral therapy (ART) response
among HIV-infected patients. Dried blood spots (DBS) are an appealing alternative to
conventional plasma-based virologic testing, improving access to monitoring in resource-limited
settings. However, validity of DBS obtained from fingerstick in field settings remains unknown.
Objectives—Investigate feasibility and accuracy of DBS vs plasma collected by healthcare
workers in real-world settings of remote hospitals in Malawi. Compare venous DBS to fingerstick
DBS for identifying treatment failure.
Study design—We recruited patients from ART clinics at two district hospitals in Malawi,
collecting plasma, venous DBS (vDBS), and fingerstick DBS (fsDBS) cards for the first 149
patients, and vDBS and fsDBS only for the subsequent 398 patients. Specimens were tested using
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Abbott RealTime HIV-1 Assay (lower detection limit 40 copies/ml (plasma) and 550 copies/ml
(DBS)).
Results—21/149 (14.1%) had detectable viremia (>1.6 log copies/ml), 13 of which were
detectable for plasma, vDBS, and fsDBS. Linear regression demonstrated high correlation for
plasma vs. DBS (vDBS: β=1.19, R2 0.93 (p<0.0001); fsDBS β=1.20, R2 0.90 (p<0.0001)) and
vDBS vs. fsDBS (β=0.88, R2 0.73, (p<0.0001)). Mean difference between plasma and vDBS was
0.51 log copies/ml [SD: 0.33] and plasma and fsDBS 0.46 log copies/ml [SD: 0.30]. At 5000
copies/ml, sensitivity was 100%, and specificity was 98.6% and 97.8% for vDBS and fsDBS,
respectively, compared to plasma.
Conclusions—DBS from venipuncture and fingerstick perform well at the failure threshold of
5000 copies/ml. Fingerstick specimen source may improve access to virologic treatment
monitoring in resource-limited settings given task-shifting in high-volume, low-resource facilities.
Background
HIV viral suppression is a key indicator of successful treatment for HIV-infected patients on
antiretroviral therapy (ART). Global treatment access initiatives have resulted in millions
receiving life-saving therapy in resource-limited settings. With over 9.7 million people
receiving ART in low- and middle-income countries, the issue of how to appropriately
monitor patients is now an urgent international issue.1-3 Feasible treatment monitoring
strategies in these settings remain unclear.
The expense and complexity of conventional plasma-based viral load (VL) tests limit their
usefulness in resource-limited settings4. The sensitivity of immunologic and clinical staging
for identifying treatment failure is highly variable and generally low5-15, thus the utility of
these approaches in driving treatment decisions has been mixed5, 6, 8, 9, 11, 16-25. Point-of-
care VL tests are under evaluation, but effective and affordable point-of-care technologies
remain unavailable26.
Use of dried blood spots (DBS) alleviates technological and cold-chain barriers, enabling
access to VL monitoring in remote settings and potentially improving identification of ART
failure27, 28. DBS from fingersticks should decrease associated costs compared to venous
DBS, task-shifting to lower-level providers and reducing consumable-associated expenses.
Fingerstick DBS may also expand monitoring to health centers without phlebotomy
capabilities29. Previous CD4 test evaluations have shown mixed results in terms of
concordance between venous and capillary specimens30, 31. Numerous studies have
suggested the opportunity for venous DBS for VL monitoring27, 29, 32-44 but ours was one of
the first tests of fingerstick DBS under true field conditions. We relied on existing clinic
personnel for specimen collection, card preparation, and transport to the central laboratory,
reflecting a more “real-world” scenario of VL monitoring using DBS via fingerstick.
Objectives
We investigated the feasibility and accuracy of using DBS in remote district hospitals in
Malawi, compared to plasma. We compared venous DBS to fingerstick DBS. This
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validation is a component of an on-going public health evaluation of feasibility and
acceptability of DBS in Malawi.
Study Design
Study population
Patients were recruited from ART clinics at two district hospitals in central and southern
Malawi. Eligibility criteria included: ≥18 years and on first-line ART for 6 months, 24
months, or any 24-month period thereafter consistent with Malawi recommendations for VL
monitoring. Patients were also eligible if they were on therapy ≥6 months and showing signs
of clinical failure (WHO Stage 3 or 4 condition). The first 149 patients had venipuncture
collected for plasma and venous DBS (vDBS) card preparation, and fingerstick for DBS
(fsDBS) card preparation. The subsequent 398 patients had vDBS and fsDBS cards
prepared. This study was approved by the National Health Sciences Research Committee of
Malawi, and the Biomedical Institutional Review Board at University of North Carolina,
Chapel Hill.
Plasma preparation
Plasma was collected by venipuncture into an EDTA collection tube. The specimen was
processed on-site within 8 hours of collection. Plasma was double-spun at 800×g for 10
minutes and stored at -20C until shipping.
Card preparation
Sites were provided DBS collection kits containing: Munktell TFN DBS card with
perforated discs45, 2-3 capillary tubes, powder-free gloves, sterile lancet, alcohol swab,
plastic zip bag, and desiccant. Each DBS card was prepared using a separate kit. Specimens
were collected by ART clinic staff: venipuncture was done by laboratory technicians, nurses
or clinical officers, and fingerstick by laboratory technicians, nurses, clinical officers, or
health-surveillance assistants (HSA). Sites chose which provider collected the specimens
based on optimal clinic flow. Cards were labeled with ART patient identifier, source of
sample (venous/fingerstick), date/time of collection, and staff initials. Venous blood was
collected into an EDTA tube, transferred into 50μl capillary tube to facilitate consistent and
reliable blood volume per spot, and the contents spotted onto the DBS card. This process
was repeated 5 times, allowing for reserve spots in the event of a failed run. Fingerstick
specimens were obtained using the sterile lancet after cleaning the finger with alcohol.
Blood from fingerstick puncture sites were collected into a 50μl capillary tube and spotted
onto the DBS card, filling 5 circles with 50μl of blood. Cards were air dried at room
temperature for at least 3 hours. Dried cards were transferred to individual zip bags with
three desiccant sachets and stored at room temperature in the specimen collection room
within the clinic or in the laboratory. Sites were instructed to keep cards out of direct
sunlight. Storage temperature was not monitored.
Transport to central laboratory
DBS and plasma specimens were transported to the central laboratory approximately
weekly. The internationally monitored research laboratory is located in the capital city
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(Lilongwe). Plasma samples were transported frozen on ice packs or dry ice. DBS cards
were transported at ambient temperature. Transport of plasma specimens was completed in
one-day (~250km or 3-4 hours from the central region hospital; ~ 350km or 6 hours from
southern region hospital). DBS cards were either driven directly by study staff or shipped
via in-country specimen shipment arriving within 2-3 days.
VL quantification
DBS and plasma specimens were tested using the Abbott RealTime HIV-1 Assay (Abbott
Laboratories, Chicago, IL) (m2000) (reportable range of 40 to 10,000,000 copies/ml for
plasma and lower limit of detection for open-mode DBS protocol of 550 copies/ml. Lower
limit of detection for open-mode protocol was determined by previous studies demonstrating
DBS VL detectable among 95.7% of plasma specimens >550 copies/ml)32. Using a sterile
pipette tip, two DBS spots were punched directly into a tube containing 1.7 mL mLysis
buffer. The tube was placed on the mixer for 30 minutes. DBS samples were extracted using
the automated m2000sp instrument and amplified according to the 1 mL DBS protocol.
Plasma specimens were tested using the 0.6 mL plasma protocol.
Statistical analysis
All RNA values are reported as copies or log10 –transformed copy numbers per ml of blood.
Undetectable results (<1.60 log copies/ml (plasma), <2.74 log copies/ml (DBS)) were
replaced with the midpoint value between 0 and lower limit of detection (1.3 log copies/ml
(plasma), 2.44 log copies/ml (DBS)). Sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) were calculated at 5,000 (3.70 log) copies/ml-
the current Malawi virological failure definition – and 1000 (3.0 log) copies/ml, the current
WHO plasma-based virological failure threshold46. Linear regression analyses were
performed comparing results across specimen types. The correlation was expressed as the
regression coefficient and R value. Given non-normal distributions, mean values of VLs
between plasma/vDBS, plasma/fsDBS, and vDBS/fsDBS were compared using non-
parametric Wilcoxon matched-pairs signed-ranks. Concordance between plasma/vDBS,
plasma/fsDBS, and vDBS/fsDBS was assessed using the Bland and Altman test. All
analyses were performed using STATA statistical software (version 13.0; StataCorp,
College Station, TX). Differences were considered significant when p-values were <0.05.
Results
Study Participants
547 ART patients (mean age 42, standard deviation [SD]10.0) were enrolled (Table 1). 149
plasma/vDBS/fsDBS (“triplicate specimens”) and 398 vDBS/fsDBS specimens were
obtained.
Turnaround time
Mean days from specimen collection to laboratory receipt was 8.3 (SD: 4.9; range: 1-28) for
plasma and 10.2 (SD: 5.5; range: 1-28) for DBS. Mean days between specimen collection
and testing was 12.2 (SD: 4.7; range: 4-25) for plasma, and 17 (SD: 7.2; range: 1-31) for
DBS.
Rutstein et al. Page 4






















Comparison of plasma to vDBS and fsDBS
Agreement between plasma/vDBS and plasma/fsDBS was 96.0% and 91.9%, respectively
(Tables 2a & 2b). Among 149 plasma specimens, 21 (14.1%) samples had detectable VL: 8
(38.1%) had VL between 1.30 and 2.74 log copies/ml; 3 (14.3%) had VL between 2.74 and
3.70 log copies/ml; and 10 (47.6%) had VL >3.70 log copies/ml. Among patients with a
detectable VL, median VL was 3.52 [interquartile range (IQR): 2.04-4.42], 4.51 [3.78 –
5.27], and 4.11 [3.29 – 5.17] log copies/ml for plasma, vDBS, and fsDBS, respectively.
Thirteen triplicates had detectable VL for all three specimen types (Table 3).
Linear regression analyses demonstrated high correlation between plasma VL and DBS
[vDBS: β=1.19, R2 0.93 (p<0.0001); fsDBS β=1.20, R2 0.90 (p<0.0001) (Figure 1a and 1b)].
Mean difference between plasma and vDBS was 1.1 log copies/ml [SD: 0.27] and plasma
and fsDBS 1.1 log copies/ml [SD: 0.31] (Figure 2a and 2b). Differences were statistically
significant by the Wilcoxon signed rank test (p<0.001).
Sensitivity of vDBS and fsDBS was 100% at the 1000 copies/ml threshold (3.0 log copies/
ml), and specificity was 97.1% and 94.9%, respectively, compared to plasma. Prevalence of
failure at 1000 copies/ml was 8.1%, corresponding to a PPV of 75.0% and 63.2% for vDBS
and fsDBS, respectively, and 100% NPV. At a cutoff of 5000 copies/ml (3.7 log copies/ml),
sensitivity remained 100% and specificity increased to 98.6% and 97.8% for vDBS and
fsDBS, respectively, compared to plasma. Despite a lower failure prevalence (6.7%) PPV
improved (83.3% and 76.9% for vDBS and fsDBS), while NPV remained 100%.
At a 5000 copies/ml threshold, vDBS and fsDBS would yield the correct clinical decision
98.7% and 98.0% of the time, respectively. We observed 3 clinically discordant triplicates in
which DBS results indicated VL >5000 copies/ml (i.e., failure) but plasma results were
<5000 copies/ml (Table 4). Using a lower threshold for defining failure (1000 copies/ml),
the rate of clinical discordancy of DBS compared to plasma increased (8 discordant results),
corresponding to making the correct clinical decision less often (97.3% (vDBS) and 95.3%
(fsDBS)).
Comparison of vDBS and fsDBS
Five-hundred forty-seven paired vDBS and fsDBS specimens were obtained, including the
149 vDBS/fsDBS pairs discussed above. Agreement for vDBS and fsDBS, in which both
vDBS and fsDBS had concordant detectable or undetectable results, was 86.8% (Table 2c).
75 vDBS and 78 fsDBS had detectable viremia (>2.74 log copies/ml). Of specimens with
detectable VL, 92.0% (69) of vDBS and 84.6% (66) of fsDBS were >3.0 log copies/ml.
45.3% (34) vDBS and 39.7% (31) fsDBS specimens were >3.70 log copies/ml. Median VL
was 2.44 [IQR 2.44 – 2.44] for both vDBS and fsDBS, demonstrating the small
subpopulation with detectable VL. Among patients with detectable VL, median VL [IQR]
was 3.42 [3.17 – 4.45] and 3.29 [3.08 – 4.40], for vDBS and fsDBS, respectively.
There was moderate correlation between vDBS and fsDBS: β=0.88, R2 0.73, (p<0.0001)
(Figure 1c). The mean difference between vDBS and fsDBS was 0.009 log copies/ml [SD:
0.30] and was not statistically significant according to the Wilcoxon signed-rank test
(p=0.267) (Figure 2c).
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Among the 547 participants with vDBS and fsDBS specimens, overall clinical concordance
at 5000 copies/ml was 98.7%. Overall concordance between vDBS and fsDBS at the 1000
copies/ml threshold was 88.8%.
Discussion
Despite rapid expansion of access to ART in resource-limited settings, appropriate treatment
monitoring strategies remain largely unavailable. The consequence of inadequate monitoring
may manifest in accumulation of drug resistance mutations, compromising the effectiveness
of future ART options. Plasma-based virologic monitoring is prohibitively complex and
expensive for routine use in resource-limited settings. DBS have been suggested as an
alternative given the relative simplicity of card preparation and the lack of cold-chain
requirements. However, the use of DBS for VL monitoring as collected and prepared in
uncontrolled, real-world field conditions is still in its infancy. Furthermore, most previous
investigations have relied on venipuncture for DBS card preparation, a potential barrier for
implementation in more remote, understaffed clinics. In the present study, we found that
DBS obtained from fingerstick prepared by non-laboratory personnel in an uncontrolled
setting compared well to both venous DBS as well as plasma for identifying virologic failure
of ART patients.
Using the threshold of virologic failure as >5,000 copies/ml, we observed excellent clinical
concordance between DBS specimens and plasma: 98.7% of vDBS and 98.0% of fsDBS
yielded identical clinical decisions as plasma. Very little data exist on the reliability on DBS
from fingerstick29: our evaluation of fsDBS confirmed acceptable correlation when
compared to plasma. Comparing fsDBS to vDBS, we observed 88.8% and 98.7% overall
agreement at 1000 and 5000 copies/ml thresholds, respectively.
We observed 100% sensitivity for both vDBS and fsDBS, compared to plasma, at failure
thresholds of 1,000 copies/ml and 5,000 copies/ml. Specificity improved at the higher
threshold for both specimens. This suggests DBS is highly feasible under current WHO
guidelines. However, at the lower threshold, DBS had lower positive predictive values
thereby potentially allowing premature switching to 2nd line therapy. Given the higher cost
of 2nd line therapy and general absence of 3rd line options, premature switching may have
long-term health consequences for the individual and cost considerations for the overall
program. Similar studies using the NucliSENS platform have observed lower sensitivity but
perfect specificity, a difference that may be due to NucliSENS only detecting HIV RNA
while Abbott will detect plasma RNA as well as intracellular HIV RNA and proviral
DNA29.
Importantly, less than 7% of all patients tested had viral loads >5,000 copies/ml and over
85% of patients were below the limit of detection. This failure prevalence is similar to that
observed elsewhere in Malawi-based studies29. Only 5% of plasma samples were between
40 and 550 copies/ml, suggesting that the higher limit of detection for DBS compared to
plasma may not be of great clinical significance.
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DBS VL estimations were universally higher than plasma. This is likely a reflection of
proviral DNA and cellular RNA contributions in DBS specimens that artificially raise the
VL values. Some have suggested use of DNase pre-step or DNase-containing filter paper to
select for RNA37, 47. We observed good clinical concordance at 5000 copies/ml failure
threshold without using DNase treatment, but additional pre-treatment steps to extract only
RNA may be necessary at lower failure thresholds. Abbott's software-imbedded conversion
factor accounts for the amount of blood per spot (based on absorbency of DBS cards), the
number of spots, the volume of spot elution buffer used per spot, the volume of spot eluate
that is processed, and hematocrit (L. Phillips, personal communication, May 3, 2014).
Inaccuracies in this experimentally-determined conversion factor, or substantially different
hematocrit between our population and the population used to determine this factor, could
contribute to systematically higher DBS VL compared to plasma. However, other
contributing elements to this conversion factor were consistent with protocol-defined
volumes, including the volume of blood per spot given our use of capillary tubes in both
vDBS and fsDBS preparations. The WHO guidelines recognize that DBS-based failure
should use a higher threshold than that driven by plasma VL.46 Larger studies may be
necessary to determine if an alternative platform-specific adjustment factor would improve
correlation of plasma and DBS VL.
We observed excellent quality of DBS specimens; fewer than 5 cards were rejected due to
poor quality. All cards were rejected within the first two-weeks of study initiation and were
generally due to blood spots failing to fill the entire outlined circle on the DBS card. This
success may be partially attributed to the two-day study training and refresher trainings
conducted at sites, during which staff were instructed on proper lancet, capillary, and DBS
card preparation technique. The specimen quality may also be related to our reliance on
HSAs and HIV Testing Counselors. Although these personnel are considered in the lower
cadres in terms of skilled providers within the Malawi healthcare system, they have
extensive experience with fingerstick specimen collection for both point-of-care HIV
antibody tests as well as early infant diagnosis.
Our study was one of the first to evaluate feasibility and accuracy of fingerstick DBS for VL
monitoring under real-world ART clinic conditions. We used eligibility criteria mirroring
Malawi Ministry of Health standards. A limitation of this operational-style research was that
our population was comprised of many patients with undetectable viremia, meaning a
smaller sample for regression and correlation analyses. Nonetheless, our findings reaffirm
the feasibility for fingerstick DBS in terms of agreement with plasma, and demonstrate
implementation potential in remote settings.
The use of fingerstick for DBS VL monitoring is a tantalizing opportunity, permitting task-
shifting to lower-level providers. Fingerstick sampling may be essential for implementation
of DBS in overburdened ART clinics in resource-limited settings. Our findings are
promising for the expansion of fingerstick DBS for routine VL monitoring.
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Linear regression comparing VL values from vDBS (a) and fsDBS (b) to plasma, and fsDBS
to vDBS (c)
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Bland and Altman plot demonstrating degree of agreement in log copies/ml between vDBS
(a), fsDBS (b), and plasma as well as fsDBS and vDBS (c), X-axis plots average VL values
for paired specimens. Y-axis represents the difference between the values obtained between
the specimen sources evaluated. The solid line represents the mean difference and the dotted
lines are the mean +/− 1.96(SD).
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